Researchers at the University of South Florida have discov-ered that inhibition of SH2 - containing inositol phospha-tase (SHIP) ameliorates transplant rejection and stimulates hematopoiesis.
Tissue rejection or graft vs host disease (GVHD) is a significant con-cern in allogenic transplant medicine. GVHD is the major cause of treatment related mortality in transplant procedures. SHIP inhibi-tion specifically works to target antigen presenting cells, thereby alleviating rejection.
Furthermore, hematopoiesis can be impaired due to disease, radia-tion, or chemotherapy. Inhibition of SHIP has been shown to stimu-late hematopoiesis by increasing homing of stem cells to the pe-riphery, and increasing megakaryocyte, granulocyte, neutrophil, and platelet production.
Potential Routes of Administration include: (1) Interfering RNA (2) Double stranded RNA or DNA (3) Polynucleotides (4) Ribozymes
Treatment for: (1) Allogeneic transplantation of solid organs or bone marrow (2) Enhancement of stem cell production (3) Myelosuppression
Brochure
